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Abstract 28	
CD4+ T cells support host defence against herpesviruses and other viral pathogens. 29	
We identified that CD4+ T cells from systemic and mucosal tissues of hosts infected 30	
with the β-herpesviridae human cytomegalovirus (HCMV) or murine cytomegalovirus 31	
(MCMV) express the regulatory cytokine interleukin (IL)-10. IL-10+CD4+ T cells co-32	
expressed TH1-associated transcription factors and chemokine receptors. Mice 33	
lacking T cell-derived IL-10 elicited enhanced antiviral T cell responses and restricted 34	
MCMV persistence in salivary glands and secretion in saliva. Thus, IL-10+CD4+ T 35	
cells suppress antiviral immune responses against CMV. Expansion of this T-cell 36	
population in the periphery was promoted by IL-27 whereas mucosal IL-10+ T cell 37	
responses were ICOS-dependent. Infected Il27rα-deficient mice with reduced 38	
peripheral IL-10+CD4+ T cell accumulation displayed robust T cell responses and 39	
restricted MCMV persistence and shedding. Temporal inhibition experiments 40	
revealed that IL-27R signaling during initial infection was required for the suppression 41	
of T cell immunity and control of virus shedding during MCMV persistence.  IL-27 42	
production was promoted by type-I IFN, suggesting that β-herpesviridae exploit the 43	
immune-regulatory properties of this antiviral pathway to establish chronicity. Further, 44	
our data reveal that cytokine signaling events during initial infection profoundly 45	
influence virus chronicity.  46	
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Author summary 56	
Viruses including the pathogenic β-herpesvirus human cytomegalovirus (HCMV) can 57	
replicate within and disseminate from mucosal tissues. Understanding how to 58	
improve antiviral immune responses to restrict virus replication in the mucosa could 59	
help counter virus transmission. Studies in the murine cytomegalovirus (MCMV) 60	
model have demonstrated the importance of the CD4+ T cells in control of mucosal 61	
MCMV replication. However, this process is inefficient, allowing virus persistence. 62	
Herein, we reveal that production by CD4+ T cells of the immune-suppressive soluble 63	
protein, or cytokine, interleukin (IL)-10 facilitates virus persistence in mucosal tissue. 64	
Mice deficient in T cell-derived IL-10 mounted heightened T cell responses and 65	
reduced virus replication in the salivary glands and shedding in the saliva. The 66	
cytokine IL-27 induced IL-10-producing CD4+ T cells in the periphery whereas a cell 67	
surface-expressed protein, ICOS, promoted mucosal IL-10+ T cell responses. IL-27 68	
acted in the initial stages of infection to impinge on T cell responses and antiviral 69	
control. In turn, IL-27 production in response to viral infection was triggered by type I 70	
interferon, a prototypic antiviral cytokine. Thus, our data suggest that herpesviruses 71	
may exploit immune-suppressive properties of this early antiviral cytokine response 72	
to facilitate persistence within and shedding from mucosal tissue.  73	
 74	
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Introduction 84	
 85	
Human cytomegalovirus (HCMV) is a ubiquitous β-herpesvirus that establishes 86	
lifelong infection. Infectious virus is usually acquired by horizontal transmission via 87	
mucosal secretions and urine. HCMV infection is typically asymptomatic in healthy 88	
individuals. However in the immunocompromised such as HIV-infected individuals 89	
and patients receiving immune-suppressive drugs, the virus can reactivate with 90	
debilitating consequences [1,2]. Further, HCMV is the leading congenital infection in 91	
the World, infecting up to 2.5% of live births and causing life-long neurological 92	
defects [3].   93	
 94	
HCMV employs a range of immune evasion strategies to facilitate persistence. These 95	
include down-regulation of MHC and co-stimulatory ligands and modulation of host 96	
cytokine production [4,5]. Notably, HCMV encodes its own ortholog of the immune-97	
regulatory cytokine interleukin (IL)-10 [6]. Two isoforms of viral IL-10 exist, both of 98	
which suppress immune cell activation in vitro [7,8] and induce expression of cellular 99	
IL-10 [9,10], suggesting the importance of the immune suppressive functions of IL-10 100	
in HCMV infection in vivo. The murine CMV (MCMV) model is well established as a 101	
model for HCMV infection in vivo due to similar cellular and tissue tropism, and 102	
comparable anti-viral immune responses [11]. While MCMV does not encode a vIL-103	
10, cellular IL-10 is induced upon infection of macrophages in vitro [12]. Data 104	
obtained from the MCMV model has demonstrated an important protective role for 105	
cellular IL-10 during acute CMV infection. Myeloid cells and B cells are the 106	
predominant sources of IL-10 during initial MCMV infection [13,14].  IL-10 limits virus 107	
induced weight loss, pro-inflammatory cytokine production and activation-induced NK 108	
cell death [13-15]. Sustained acute MCMV replication in situations of high virus load 109	
also induces IL-10 production by NK cells that restricts CD8+ T cell-mediated immune 110	
pathology [16]. In contrast, production of IL-10 during chronic MCMV infection 111	
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suppresses viral clearance. Indeed, IL-10-deficient mice exhibit dramatic expansions 112	
of virus-specific T cell responses, reduced virus persistence in the salivary glands 113	
[14] and fewer viral genome copies in peripheral tissues during chronic/latent 114	
infection [17]. Furthermore, persistent MCMV replication in the salivary glands is 115	
dramatically restricted by the blockade of IL-10R signaling [18]. These data suggest 116	
that although blocking the action of IL-10 during acute CMV infection may be harmful 117	
to the host, targeting IL-10-mediated regulation of antiviral T cell responses may 118	
impinge on virus chronicity and restrict horizontal virus transmission via mucosal 119	
surfaces.  120	
 121	
Previous studies have shown that TH1 cells can produce IL-10 under certain 122	
conditions [19-24]. IL-10 producing TH1 cells have been shown to be protective in 123	
parasitic infections by limiting infection-related pathology [24-26]. However, in the 124	
context of lymphocytic choriomeningitis (LCMV) infection, virus replication is 125	
accompanied by the production of IL-10+ T cells [27,28], and genetic deletion of IL-10 126	
within T cells (or LysM+ cells) reduces virus chronicity [29]. HCMV-encoded latency 127	
associated antigens induce CD4+/IL-10+ responses in healthy donors [30]. MCMV-128	
specific IL-10 production by CD4+ T cells has also been described [17,31,32], and 129	
CD4+ cell-derived IL-10 suppresses control of virus replication and leukocyte 130	
accumulation during acute MCMV infection [33]. A substantial proportion of CD4+ T 131	
cells express IL-10 upon polyclonal stimulation in salivary glands during MCMV 132	
persistence [18]. However it is currently unknown how the expansion of these cells is 133	
controlled during infection, and whether IL-10 production by T cells impacts on 134	
MCMV chronicity . 135	
 136	
Type-I IFNs are prototypic antiviral cytokines that exert important control of viral 137	
replication. However inappropriate type-I IFN responses promote pathogenesis 138	
associated with acute viral infections, and prolonged expression of type-I IFNs in 139	
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chronic viral infections including human immunodeficiency virus and hepatitis B virus 140	
is implicated in driving immune pathology and antagonizing antiviral T cell responses 141	
(reviewed in [34]). Further, in the LCMV model of infection, blockade of type-I IFN 142	
receptor signaling in certain situations may enhance CD4+ T cell immunity and 143	
control of virus chronicity, an outcome associated with reduced development of 144	
immune-suppressive DCs [35,36]. Although type-I IFN is critical for early control of 145	
CMV replication [37], the role that type-I has in shaping adaptive immunity during 146	
CMV infection in incompletely understood.  147	
 148	
The IL-12 family member IL-27 exhibits a broad spectrum of functions, including the 149	
regulation of infection-induced pathologies (reviewered in [38]). Indeed, experiments 150	
in murine influenza infection demonstrated that IL-27 restricts virus-induced 151	
pathology associated with exuberant neutrophil, TH1 and TH17 responses [39]. IL-27 152	
induces IL-10 expression by CD8+ T cells [40-42], and IL-27-dependent control of 153	
influenza-induced inflammation is partially dependent upon IL-10 [39]. However, IL-154	
27 impairs control of acute mouse hepatitis replication and associated pathology 155	
following infection of the CNS and this phenotype is associated with reduced 156	
accumulation of IL-10+ CD4+ T cells [43]. Paradoxically, IL-27 exerts cell intrinsic 157	
positive regulation of antiviral CD4+ T cell responses during chronic LCMV infection, 158	
promoting control of virus replication [44]. Moreover, IL-27 inhibits replication of both 159	
HIV and HCV via the induction of interferon-stimulated genes [45,46], suggesting that 160	
IL-27 is beneficial to the host during chronic viral infections. 161	
 162	
Herein we investigated the role that IL-10+CD4+ T cells play in regulation of MCMV 163	
specific T cell immunity. We identified that T cell-derived IL-10 suppressed T cell 164	
response during persistent infection and subsequently promoted chronic virus 165	
replication. We revealed that an axis involving type-I IFN and IL-27 promotes the 166	
generation of peripheral IL-10-producing T cells that suppress antiviral immunity, 167	
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suggesting that CMV exploits this immune-regulatory pathway induced early in 168	
infection to ensure viral persistence within mucosal tissue. 169	
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Results 196	
 197	
Virus-specific CD4+ T cells produce IL-10 during MCMV infection in peripheral 198	
and mucosal tissue 199	
We previously demonstrated that CD4+ but not CD8+ T cells produce IL-10 during 200	
MCMV infection of the salivary glands, and that IL-10 promotes MCMV persistence 201	
[18]. Therefore we sought to assess virus-specific CD4+ T cell production of IL-10 202	
over time. Using a panel of MHC class II-restricted peptides identified to induce CD4 203	
T cell responses during acute and persistent MCMV infection [32], we first defined 204	
the antigen hierarchy of CD4+/IL-10+ production in both the mucosa and periphery 205	
during MCMV infection using CD4-Cre-IL-10flox/flox (Cre-) mice, and mice lacking T cell 206	
derived IL-10 (CD4-Cre+IL-10flox/flox, Cre+) as controls for IL-10 staining. In accordance 207	
with data derived from polyclonally-stimulated CD4+ T cells [18], high frequencies of 208	
virus-specific IL-10+CD4+ T cells were observed in salivary glands after MCMV 209	
infection (Fig. 1A&B), peaking at d14 post-infection (pi). Frequencies of salivary 210	
gland IL-10+CD4+ T cells were substantially higher than CD4+ T cells producing IFNγ 211	
(Fig. 1C) suggesting that, at this time-point, IL-10+ T cells were the dominant MCMV-212	
specific T cell response. We also detected virus-specific CD4+/IL-10+ T cells in the 213	
periphery (Fig. 1A&D), highlighting that IL-10 production was not restricted to 214	
mucosal CD4+ T cells [14,32]. The peripheral IL-10+CD4+ T cell response reactive to 215	
M25, m142 and, to a lesser extent, m139, peaked during acute infection d7 pi (Fig. 216	
1D) although, unlike salivary gland responses, were not present at higher 217	
frequencies than IFNγ+ cells (Fig. 1E). Splenic IL-10+ CD4+ T cell frequencies also 218	
contracted rapidly, remaining at low but significant levels during the remaining course 219	
of infection.  220	
 221	
 222	
 223	
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Figure 1. Virus-specific CD4+ T-cells produce IL-10 during MCMV infection 224	
CD4-Cre-IL-10flox/flox (Cre-) mice were infected with MCMV and at day 7, 14, 30 and 60 pi 225	
leukocytes from the salivary glands (A-C &F) and spleen (A, &D-F) were isolated. (A) 226	
Representative bivariant FACS plots of IL-10 versus IFNγ expression by viable (aqua 227	
live/dead
-) salivary gland (top) and splenic (bottom) CD4+CD3+ cells. CD4+/IFNγ+ and 228	
CD4
+
/IL-10+ responses were measured after 6-hour stimulation with m09, M25, m139 229	
and m142 MHCII MCMV antigens. Data is shown as mean ± SEM percent IL-10+ (B&D) 230	
and percent + SEM IFNγ
+ (C&E) CD4+ cells and (F) IL-10+, IFNγ+ and double positive 231	
cells over time. Data represents 8-16 mice per group and is representative of 2-3 232	
experiments per time-point. 233	
 234	
 235	
MCMV-specific CD4+/IL-10+ cells express T-Bet  236	
MCMV-induced IL-10+CD4+ T cells do not express TH2-associated cytokines or the 237	
regulatory T cell-associated transcription factor FoxP3 [18]. IL-10 is expressed by 238	
numerous T helper subsets, including TH1 cells [24,25]. Interestingly, although a 239	
small CD4+IFNγ+IL-10+ response was detected in the spleen after stimulation with 240	
peptide for 6 hours, few co-producing cells were detected in the salivary glands upon 241	
stimulation with cognate peptide (Fig. 1A&F), whereas MCMV-induced IL-10+CD4+ T 242	
cells in the spleen and salivary glands can co-express IFNγ when poly-clonally 243	
stimulated with PMA and ionomycin. 244	
 245	
To further investigate the phenotype of IL-10+CD4+ T cells, we performed 246	
transcription factor profiling of these cells using 10-BiT reporter mice that express the 247	
surface marker CD90.1 (Thy1.1) under control of the IL-10 promoter without 248	
impacting on endogenous IL-10 production [47]. We studied CD4+IL-10+ cells in the 249	
spleen and salivary glands at peak responsiveness (d7 and d14, respectively). In 250	
accordance with the ability to express IFNγ in response to polyclonal stimulation, 251	
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significant expression of the TH1-associated transcription factor T-Bet was observed 252	
in salivary gland and, to a lesser extent, splenic Thy1.1+ CD4+ T cells (Fig. 2A-C). In 253	
contrast, Thy1.1+ CD4+ T cells did not express the TH17-associated transcription 254	
factor, aryl hydrocarbon receptor, nor did they co-express Tr1 cell markers CD49b 255	
and LAG-3 (S1 Figure). Instead, splenic Thy1.1+ CD4+ T cells co-expressed the TH1-256	
associated chemokine receptors CXCR3 and CCR5 (Fig. 2D). Although Thy1.1+ and 257	
Thy1.1- salivary gland CD4+ T cells expressed low levels of CXCR3 and CCR5 14 258	
days pi (Fig. 2D), high expression of their cognate chemokines during salivary gland 259	
MCMV infection [48] is consistent with the hypothesis that these receptors are 260	
internalized upon binding to their chemokine ligands within infected tissue.   261	
 262	
To further explore the transcription control of IL-10 production by CD4+IL-10+ cells, 263	
we examined the expression of Blimp-1 and c-Maf [49]. Significant expression of both 264	
transcription factors was detected in Thy.1.1+ cells from the spleen and salivary 265	
glands of infected mice (Fig. 2A-C). Furthermore, with the exception of Blimp-1 266	
expression by salivary gland CD4+ T cells, increased expression of T-Bet, Blimp-1 267	
and c-Maf by Thy1.1+ was measured as compared to Thy1.1- cells (Fig. 2A-C). 268	
Overall, the combination of transcription factor and chemokine receptor expression of 269	
IL-10+CD4+ T cells induced in response to MCMV indicated that these cells 270	
originated from a TH1 lineage.  271	
 272	
Figure 2. Transcription factor profiling of CD4+/IL-10+ producing T cells  273	
10-BiT reporter mice were infected with MCMV and at day 7 and d14 pi spleen and 274	
salivary glands were isolated. (A) Representative bivariant FACS plot of viable (aqua 275	
live/dead
-) Thy1.1 expression by CD4+CD3+ cells (top) and representative histograms of 276	
T-Bet, BLIMP-1 and c-maf expression or (D) contour FACS plot of CXCR3/CCR5 277	
expression by Thy1.1
-
 or Thy1.1
+
 CD4
+
CD3
+
 cells. Control = fluorescent minus one-278	
stained Thy1.1
+
 samples from each time-point. (B&C) Intensity of transcription factor 279	
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staining by CD4+CD3+ cells in the spleen (B) and salivary glands (C) is shown as mean + 280	
SEM of 5-6 mice/group and is representative of 2 separate experiments. 281	
 282	
 283	
HCMV specific T-cells in peripheral blood and mucosal tissue secrete IL-10 284	
We next asked whether HCMV-specific T cells reactive to common HCMV antigens 285	
would also produce IL-10. Healthy colon and peripheral blood was obtained from 286	
colorectal cancer (CRC) patients undergoing colonic resection and we assessed 287	
glycoprotein B (gB, UL55) and tegument (pp65, UL83) specific IL-10/IFNγ production 288	
using fluorospot. As compared to the low baseline IL-10/IFNγ production by medium-289	
stimulated T cells (Fig. 3A), notable albeit variable frequencies of pp65 and gB 290	
specific cytokine production were measured in blood (Fig. 3B). Interestingly, IL-10 291	
production dominated pp65- and gB-specific responses in 3 of 4 and 2 of 4 patients, 292	
respectively (Fig. 3B). Importantly, we also detected HCMV-specific cytokine 293	
production in leukocytes isolated from the colon (Fig. 3A&B), demonstrating the 294	
presence of HCMV-specific IL-10-producing T cells in human mucosal tissues. To 295	
confirm HCMV-specific IL-10 production was derived from CD4+ T cells, larger 296	
volumes (50mls) of blood were drawn from healthy donors, enabling the purification 297	
of CD4+ T cells prior to peptide stimulation. Again, both CD4+/IFNγ+ and CD4+/IL-10+ 298	
cells were observed following stimulation with pp65 and, to a far lesser extent, gB 299	
peptide pools (Fig. 3A&B). As observed in MCMV infection (Fig. 1A&F), very few 300	
virus-specific cells co-produced IL-10 and IFNγ (Fig. 3A&B). Thus, overall, these data 301	
demonstrate the presence of HCMV-specific IL-10+ T cells in mucosal tissue and 302	
peripheral blood. 303	
 304	
Figure 3. HCMV specific T-cells in peripheral blood and mucosal tissue secrete 305	
IL-10 306	
(A) Total leukocytes from colon and peripheral blood (left) or peripheral blood CD4+ T-307	
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cells isolated by negative selection (right) were isolated from colorectal patients 308	
undergoing surgery (left) or HCMV sero-positive healthy donors (right) were stimulated 309	
with γ-irradiated autologous targets that were pre-pulsed with vehicle control, pp65 or gB 310	
peptide pool. γ-irradiated autologous targets pre-pulsed with vehicle control or pp65 is 311	
also shown from healthy CMV sero-positive individuals. After 16hrs, cytokine expression 312	
was analyzed using a human IFNγ/IL-10 fluorospot kit where green spots represent 313	
IFNγ
+
 cells, red spots represent IL-10+ cells and yellow spots indicate dual IFNγ+/IL-10+ 314	
cells. (B) Peptide-specific spot forming cell (SFC) were calculated after subtraction of 315	
SFCs in medium-stimulated wells. Data is expressed as mean + SEM of duplicate 316	
values. Individual donors are shown. 317	
 318	
 319	
T cell derived IL-10 restricts MCMV-specific T cell immunity 320	
We sought to investigate the impact of IL-10 production by CD4+ T cells on CMV-321	
specific immunity in vivo. We utilized CD4-Cre+IL-10flox/flox (Cre+) mice in which CD4+ 322	
cells do not produce IL-10. We detected no compensatory IL-10 production by other 323	
leukocytes in response to MCMV in these mice (S2 Figure). As compared to CD4-324	
Cre-IL-10flox/flox (Cre-) control mice, Cre+ mice mounted elevated CD4+/IFNγ+ 325	
responses in the salivary glands to multiple MCMV antigens throughout the course of 326	
infection (Fig. 4A), most notably M25- and m142-specific cells at d14 pi when peak 327	
IL-10+ responses were observed in Cre- mice (Fig. 1B). The absence of CD4+ cell-328	
derived IL-10 also consistently increased the accumulation of peripheral virus-329	
specific IFNγ+ CD4+ T cells during the persistent phase of infection from d14 pi (Fig. 330	
4B), supporting the hypothesis that initial production of IL-10 by T cells in the 331	
periphery impinged on later TH1 cell accumulation.  332	
 333	
It has been shown that IL-10 deficiency leads to an increased splenic DC 334	
accumulation and expression of co-stimulatory ligands during acute infection [14]. 335	
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Cre+ mice exhibited no notable increased accumulation of splenic DCs or salivary 336	
gland myeloid cells either d7 or d14 pi (S3 Figure). However, we observed an 337	
increased frequency of myeloid cells expressing co-stimulatory ligands previously 338	
demonstrated to enhance MCMV-specific T cell responses during virus persistence 339	
[50-52], in the spleens (d7 and d14 pi) and salivary glands (d7 pi) of Cre+ mice (S3 340	
Figure). Although we report some inter-experiment variability regarding the impact of 341	
T cell-derived IL-10 on myeloid cell CD86 expression, collectively these data are 342	
consistent with a role for T cell-derived IL-10 in modulating myeloid cell function. 343	
Furthermore, in accordance with elevated CD4+ T cell responses in Cre+ mice (Fig. 344	
4A&B), we observed an increased accumulation of MCMV-specific CD8+ T-cells in 345	
peripheral tissues (Fig. 4C). As observed in studies of IL-10-/- mice [17], T cell-346	
derived IL-10 preferentially suppressed CD8+ T cell responses reactive to IE3 (Fig. 347	
4C), consistent with observation that IE3-specific CD8+ T cell inflation is particularly 348	
dependent upon CD4+ T cell help [53].  349	
 350	
Figure 4. T cell-derived IL-10 impairs anti-MCMV T cell immunity and promotes 351	
virus persistence 352	
CD4-Cre-IL-10flox/flox(Cre-) and CD4-Cre+IL-10flox/flox (Cre+) mice were infected with MCMV 353	
and at day 7, 14, 30 and 60 pi peptide-specific CD4+ IFNγ+ responses in the salivary 354	
glands (A) and spleen (B) were measured. Data is shown as mean ± SEM of cell 355	
numbers with mean of 8-17 mice per group. (C) Splenic (top) and pulmonary (bottom) 356	
virus-specific CD8+ T cells were quantified with tetramers refolded around peptides from 357	
MCMV antigens IE3, M38, m139 and M45. Total CD8+/CD3+ Tetramer+ cells are plotted 358	
with 4-8 mice per group representative of 2 experiments. (D) Replicating virus in salivary 359	
gland homogenates at day 7, 14 and 28 pi were measured by plaque assay. Data is 360	
shown as individual mice + median and represents 2-3 experiments. (E) Viral genomes 361	
were measured in saliva by qPCR day 7, 14, 21 and 28 pi. Data is shown as mean ± 362	
SEM from 5 mice/group from 3 replicative experiments. (F) Replicating virus in salivary 363	
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gland homogenates d14 pi in rag1
-/-
 mice following transfer of WT or IL-10-/- CD4+ T cells. 364	
Data is shown as individual mice + median and represents two separate experiments. 365	
 366	
 367	
The absence of IL-10 production by CD4+ T cells controls viral replication 368	
without inducing autoimmunity 369	
Unlike experiments performed in BALB/c mice [33], we detect no significant virus 370	
replication in the salivary glands during acute infection of C57BL/6 mice (Fig. 4D). 371	
Reduced persistent virus replication is observed in salivary glands of Il-10-/- mice [14] 372	
and in WT C57BL/6 mice in which IL-10R signaling is antagonized [18]. Associated 373	
with elevated CD4+ T cell responses d14 pi in Cre+ mice, fewer replicating virions 374	
were detectable in salivary glands as compared to controls. Furthermore, 5 out of 10 375	
Cre+ mice had cleared replicating MCMV by d30 pi whereas MCMV replication was 376	
detectable in all Cre- mice (Fig. 4D). Importantly, reduced virus load in Cre+ mice was 377	
accompanied by decreased shedding of virus in the saliva throughout the course of 378	
infection (Fig. 4E). Furthermore, improved control of virus replication in Cre+ mice 379	
was not accompanied by virus-induced Sjögrens Syndrome-like disease, as 380	
demonstrated by comparable salivary gland accumulation of TRAILR-expressing 381	
CD4+ T cells and serum Sjögren Syndrome Antigen (SSA)-specific IgG (S4 Figure), 382	
both of which are implicated in this disease [54]. 383	
 384	
One possible caveat of studies using CD4-cre mice is that CD8+ T cells (that express 385	
CD4 during thymic development) and CD4+ dendritic cells also lack IL-10 expression. 386	
To prove that IL-10 derived from CD4+ T-cells facilitated MCMV persistence, we 387	
negatively selected CD4+ T-cell from WT or Il-10-/- mice and adoptively transferred 388	
cells into rag1-/- mice. Whereas transfer of WT CD4+ T cells reduced MCMV titers by 389	
1 log 14d pi, Il-10-/- T cells reduced virus load by 2 logs (Fig. 4F), comparable to virus 390	
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load in Cre+ mice at this time-point (Fig. 4D). Thus, two independent approaches 391	
supported the conclusion that CD4+ T cell derived IL-10 facilitate MCMV persistence. 392	
 393	
MCMV-induced IL-27 is secreted during acute infection and promotes the 394	
development of splenic IL-10+ CD4+ T cells  395	
We sought to define the factors promoting the generation of CD4+IL-10+ T cells. IL-27 396	
is a potent inducer of IL-10 production [38]. We detected a substantial IL-27 p28 397	
production during acute MCMV infection in the spleen that peaked d2 pi (Fig. 5A). 398	
Elevated IL-27 production in the salivary glands during viral persistence was also 399	
detected, albeit much lower than concentrations measured in the spleen (Fig. 5A). IL-400	
27 is produced by multiple cells types with predominant expression by myeloid cells 401	
[55]. In accordance, we detected a high frequency of IL-27+ splenic DCs (Fig. 5B&C) 402	
and, to a lesser extent, macrophages, neutrophils and also B cells (Fig. 5B&C).  403	
 404	
Figure 5. MCMV infection induces myeloid cell expression of IL-27 during acute 405	
infection 406	
Spleen and salivary glands were isolated from naïve Cre- mice or after 2 and 4 days of 407	
infection. (A) IL-27 release was measured in tissue homogenate supernatants by ELISA. 408	
(B&C) IL-27p28 expression by DCs (MHCII+/CD11c+/Ly6C+), Macrophages 409	
(CD11b+/F480+/Ly6C+), B-cells (B220+/Siglec-H-), Neutrophils (Ly6G+) and T-cells (CD3+) 410	
was assessed by intracellular cytokine staining and is shown as mean + SEM of %IL-27 411	
release or by representative concatenated bivariate FACS plots (C). Gating was 412	
determined using fluorescent minus one-stained samples from d2-infected mice. Data is 413	
shown as 8 mice per group and is representative of at least 2 experiments. 414	
 415	
 416	
To establish the link between CMV-induced IL-27 production, and the generation of 417	
IL10+CD4+ T cells, the following experiments were conducted. Il-27rα-/- (wsx1-/-) mice 418	
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were employed which do not respond to IL-27 as a consequence of the loss of the IL-419	
27 receptor complex. Development of splenic IL-10+CD4+ T cells during acute 420	
infection was almost completely abrogated in Il-27rα-/- (wsx1-/-) mice, as were the 421	
smaller frequencies of IL-10+ cells present d14 pi (Fig. 6A&B). In contrast, 422	
development of IL-10+CD4+ T cells in the salivary glands was comparable in WT and 423	
Il-27rα-/- mice (Fig. 6A). The common IL-27 cytokine receptor glycoprotein 130 424	
(gp130) is down-regulated by virus-specific memory T cells [41] and IL-10+ (Thy1.1+) 425	
and IL-10- (Thy1.1-) CD4+ T cells in the salivary glands d14 pi expressed less gp130 426	
than splenic T cells isolated d7 pi (Fig. 6C&D). Importantly, salivary gland IL-10+ T 427	
cells expressed high levels of the co-stimulatory molecule ICOS (Fig. 6E) that has 428	
previously been implicated in the development of IL-10-secreting CD4+ T cells during 429	
viral infection [56]. Monoclonal antibody blockade of ICOS from 6 days pi significantly 430	
inhibited the development of salivary gland MCMV-specific IL-10+CD4+ T cells 14 431	
days pi (Fig. 6F). In contrast, splenic IL-10+CD4+ T cells were unaffected by ICOS 432	
blockade (Fig. 6G). These data suggest that differential signals are responsible for 433	
induction of MCMV-specific IL-10+ T cells in different tissues during MCMV infection.  434	
 435	
Figure 6. IL-27 promotes splenic CD4+IL-10+ T cell development whereas ICOS is 436	
required for salivary gland CD4+IL-10+ T cell accumulation. 437	
Il-27rα-/- or WT (C57BL/6) mice were infected with MCMV and spleen and salivary 438	
gland CD4+/IL-10+ (A) responses were quantified and expressed at mean + SEM of 439	
11 mice/group. (B) Representative bivariant FACS plots of IFNγ versus IL-10 440	
expression by splenic CD4+CD3+ T cells. (C&D) gp130 and (E) ICOS expression by 441	
IL-10+ (Thy1.1+) and IL-10- (Thy1.1-) CD4+CD3+ T cells was assessed in 10-Bit mice 442	
and shown as representative FACS plots (C) and histogram overlays (E) with mean + 443	
SEM of 5-6 mice/group (D). Gating was determined using Thy1.1- CD4+CD3+ cells 444	
derived from fluorescent minus one-stained samples from mice infected for 14 days. 445	
(F&G) WT (C57BL/6) mice were infected with MCMV and at d6 and d10 pi αICOS or 446	
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Isotype antibody was added. At d14 pi (A) salivary glands and (B) spleen CD4+/IL-447	
10+ responses were quantified and expressed at mean + SEM of 6 mice/group. 448	
 449	
	450	
IL-27 suppresses the development of antiviral TH1 immunity and promotes 451	
MCMV persistence  452	
Given the reduced splenic IL-10+CD4+ T cell accumulation in Il-27rα-/- mice, we asked 453	
whether antiviral TH1 responses were enhanced. IL-27R deficiency did not influence 454	
virus-specific TH1 responses during acute infection (Fig. 7A). However, in 455	
accordance with data derived from Cre+ mice, Il-27rα-/- mice exhibited a significantly 456	
increased accumulation of virus-specific TH1 cells within the periphery and salivary 457	
glands during the persistence phase of infection (Fig. 7A). As observed in Cre+ mice 458	
(Fig. 4C), elevated TH1 cell were also accompanied by increased virus-specific CD8
+ 459	
T-cell response d30 pi (S5 Figure). In contrast, blockade of ICOS from 6 days pi did 460	
not enhance virus-specific IFNγ+CD4+ T cell responses either in the spleen or 461	
salivary glands 14 days pi (S6 Figure), suggesting a dominant inhibitory effect of IL-462	
27-dependent IL-10+ T cell responses during the first 14 days of MCMV infection.   463	
 464	
Given that IL-27 induction of IL-10 significantly impaired anti-MCMV T cell immunity, 465	
our attention focused on whether IL-27 impacted on viral persistence. In the absence 466	
of IL-27 signaling, viral load was decreased d14 pi and MCMV replication was absent 467	
in salivary glands of most mice by d30 pi (Fig. 7B). Furthermore, we detected a 468	
significant decrease in virus shedding by Il-27rα-/- mice in the saliva, with few viral 469	
genomes detected in the saliva by d30 pi (Fig. 7C). These data are consistent with 470	
the hypothesis that IL-27 induction of IL-10+CD4+ T cells in the periphery during 471	
acute infection contributes to the suppression of TH1 immunity and subsequent viral 472	
persistence and transmission. 473	
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Figure 7. IL-27 promotes CD4+IL-10+ development and impairs anti-MCMV TH1 474	
immunity and control of MCMV persistence 475	
Il-27rα-/- or WT (C57BL/6) mice were infected with MCMV and spleen and salivary 476	
gland CD4+/IFNγ+ (A) responses were quantified and expressed at mean + SEM of 477	
11 mice/group. (B) Replicating virus in salivary gland homogenates of Il-27rα-/- and 478	
WT mice is shown as individual mice + median. Data is representative of 2 479	
experiments. (C) MCMV genomes in saliva were quantified by qPCR. Data is shown 480	
as mean ± SEM from 11 mice per group from 2 replicative experiments. 481	
 482	
 483	
MCMV-induced IL-27 production during acute infection is dependent upon 484	
type-I IFN and promotes virus persistence 485	
We examined the factors regulating IL-27 production in response to MCMV. Type-I 486	
interferon exerts critical control of MCMV infection in vivo [57,58]. However, type-I 487	
IFN induction of IL-27 during bacterial infection has been described [59]. Hence a 488	
paradoxical situation may arise where type-I IFN controls CMV on one hand, but 489	
induces IL-27 leading to inferior control of persistent virus replication. We examined 490	
whether type-I IFN orchestrated IL-27 production in response to MCMV, using an 491	
established in vitro MCMV infection system of bone marrow-derived macrophages 492	
[60]. Productive infection of WT macrophages induced substantial IL-27 mRNA 493	
expression, peaking 6hrs pi (Fig. 8A). Similarly, IL-27 expression was also maximally 494	
induced 6hrs pi with by a non-productive viral replication, as demonstrated using 495	
replication-deficient (ΔIE3) MCMV. As the primary macrophage response to viral 496	
infection involves type-I IFN signaling we next directly tested the dependency of IL-27 497	
induced expression in macrophages that are genetically ablated for either IFNβ 498	
production or type-I IFN signaling. MCMV infection of either Ifnβ-/- or Ifnαr-/- 499	
macrophages failed to induce IL-27, a result further mirrored by IFN-dependent IL-27 500	
expression upon stimulation with the TLR3 agonist, Poly:IC (Fig. 8A). Moreover, 501	
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administration of a blocking anti-IFNαR-1 monoclonal antibody during MCMV 502	
infection in vivo inhibited IL-27 expression by all cellular subsets examined (Fig. 8B). 503	
In the case of macrophages, B-cells and neutrophils, IL-27 production was almost 504	
completely abrogated by IFNαR-1 blockade (Fig. 8B). To examine whether early IFN-505	
induced IL-27 production shaped antiviral responses, we treated MCMV-infected 506	
mice with neutralizing anti-IL-27 antibody at the time of infection (Fig. 8C). IL-27 507	
neutralization significantly enhanced total virus-specific TH1 responses and reduced 508	
virus shedding 14 days pi (Fig. 8D&E) whilst concurrently reducing accumulation of 509	
virus-specific IL-10+CD4+ T cells in the spleen at this time (Pooled m09, M25, m139 510	
and m142-specific CD4+IL-10+ T cells:  Isotype control = 0.00162 × 107 cells versus 511	
αIL-27 treated group = 0.000908 × 107 cells). Importantly, IL-10R blockade from the 512	
time of IL-27-induced IL-10+ T cell responses (from day 6 pi) had no additional 513	
inhibitory influence on IFNγ+ T cell responses and virus shedding (Fig. 8D&E). Thus, 514	
IL-27 production in response to MCMV is dependent upon type-1 IFNR signaling, and 515	
this axis acts during the initial days of infection to promote the accumulation of 516	
MCMV-specific IL-10+CD4+ T cells, subsequently promoting virus persistence and 517	
shedding from the mucosa.  518	
 519	
Figure 8. Type-I IFN induces IL-27 expression during MCMV infection 520	
(A) Heat map of IL-27 p28 mRNA expression by WT, IFNβ-/- and IFNαR-/- macrophages 521	
following stimulation with WT MCMV (C3X), replication-deficient (ΔIE3) MCMV or 522	
poly(I:C). (B) Expression of IL-27 p28 by splenic leukocytes was assessed d2 pi in Cre- 523	
mice treated/not with 2 mg anti-IFNαR-1. Mean + SEM of 8 mice/group is shown and 524	
data is representative of 2 separate experiments. (C) WT (C57BL/6) mice were infected 525	
with MCMV treated with anti-IL-27, Isotype or virus alone. At d6 pi mice were treated 526	
/not with anti-IL-10R and at d14 pi spleen CD4+/IFNγ+ (D) responses were quantified 527	
and expressed as mean ± SEM of 4-15 mice/group. (E) MCMV genomes in saliva 528	
were quantified by qPCR. Data shown as mean ± SEM from 4-15 mice/ group. 529	
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Discussion 530	
 531	
Herein we reveal that cytokine responses induced upon acute MCMV infection 532	
influence antiviral T cell responses and virus replication during pathogen persistence. 533	
We identified that IL-27, which was produced by myeloid cells during the initial days 534	
of infection, promoted the generation of IL-10+CD4+ T cells in the spleen. Our data 535	
suggest that this IL-27-dependent induction of peripheral IL-10+CD4+ T cells was 536	
sufficient to impinge on T cell mediated control of virus chronicity in the mucosa. IL-537	
27 production was dependent upon type I IFN, implying that CMV exploits the 538	
immune-regulatory actions of this prototypic antiviral cytokine pathway to enable 539	
persistence and dissemination. 540	
 541	
The dynamics of virus-specific IFNγ versus IL-10 production by CD4+ T cells 542	
suggested that contraction of the IL-10 response preempts expansion of IFNγ+ T cell 543	
numbers and subsequent control of virus replication. Preventing IL-10 production by 544	
T cells both enhanced and accelerated the generation of virus-specific TH1 545	
responses. These data suggest that IL-10+ T cells provide a window of opportunity 546	
for MCMV to replicate within and shed from the salivary glands. Conversely, these 547	
results also imply that inhibiting virus-specific IL-10+ T cell development may be 548	
therapeutically beneficial. Our data suggest that peripheral IL-10+ T cells inhibit the 549	
control of virus replication within mucosal tissue independently of mucosal IL-10+ T 550	
cell populations, highlighting that appropriate modulation of peripheral T cell 551	
responses via systemic vaccination approaches may be capable of overcoming 552	
inhibitory pathways that act in the mucosa, thus enabling effective control of virus 553	
replication within mucosal tissues.   554	
 555	
Using a combination of conditional knockout mice and a cell transfer model, we 556	
demonstrated an important role for CD4+ T cell-derived IL-10 in facilitating MCMV 557	
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persistence. This result is in apparent contradiction to bone marrow chimera 558	
experiments suggesting no role for CD4+ cells in IL-10-mediated chronic MCMV 559	
replication [14]. There are several explanations for these apparent discrepancies. 560	
Firstly, whereas we used salivary gland-propagated Smith strain MCMV in our 561	
experiments, Mandaric et al examined tissue culture-propagated virus deficient in 562	
m157, a viral ligand for the NK cell activating receptor Ly49H [61]. These viruses 563	
likely replicate with different kinetics and, possibly, tropisms that may influence the 564	
induction of IL-10 expression by T cells and other cells. Furthermore, the mixed 565	
chimera experiments performed by Mandaric et al used IL-10-/- mice as recipients 566	
whereas our experiments were performed in mice from IL-10-sufficient backgrounds. 567	
Given that the time-point assessed by Mandaric et al (d14 pi) was prior to the 568	
maximal impact of CD4-derived IL-10 in our model, such variations in experimental 569	
design may influence the impact of CD4+ T cell-derived IL-10 on virus persistence.  570	
 571	
Importantly however, significant expression of IL-10 by HCMV-specific T cells in 572	
peripheral blood and mucosal tissue highlights the potential importance of T cell-573	
derived IL-10 in regulating anti-CMV immunity and viral persistence, as suggested by 574	
findings obtained from our model of chronic MCMV infection, and further supported 575	
by experiments studying acute MCMV infection [33]. HCMV-specific IL-10 production 576	
was detected in response to common lytic antigens pp65 and gB, although T cell 577	
responsiveness to gB was low in peripheral blood of all healthy volunteers examined. 578	
IL-10 production by CD4+ T cells reactive to latency-associated HCMV antigens have 579	
also been described [30]. Persistent shedding of HCMV shedding in children is 580	
associated with poor TH1 responses [62]. Our data derived from murine experiments 581	
demonstrates that preventing the generation of HCMV-specific IL-10+ CD4+ T cells 582	
may be beneficial for the improvement of protective T cell immunity following 583	
vaccination, particularly in the context of restricting horizontal transmission via 584	
mucosal surfaces.   585	
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IL-27 promoted the development of splenic but not salivary gland IL-10+CD4+ T cells. 586	
Why IL-27 had no impact on salivary gland CD4+IL-10+ accumulation is incompletely 587	
understood. Salivary glands APCs, which are phenotypically indicative of tissue-588	
resident macrophages [63], are tightly regulated via inhibitory signals such as CD200 589	
expressed by endothelial cells [60]. Thus, restricted activation of this cell population 590	
may contribute to the relatively low IL-27 production measured in this organ. 591	
Furthermore, the infection phase may also influence the impact of IL-27 on IL-10+ T 592	
cell development. Memory CD8+ T cells generated in influenza infection down-593	
regulate gp130 [41] and CD4+ T cells in persistently-infected salivary glands 594	
expressed less gp130 expression than splenic CD4+ T cells during acute infection. 595	
This down-regulation of gp130 correlated with a reduced impact of IL-27R signaling 596	
on salivary gland IL-10+ CD4+ T cell accumulation during virus persistence.  597	
 598	
Instead, ICOS co-stimulation was required for the accumulation of IL-10+CD4+ T cells 599	
within the salivary glands, thus demonstrating that differential signals promote IL-10+ 600	
T cell responses in different anatomical locations of MCMV infection and suggesting 601	
that ICOS acts independently of IL-27 in the induction of salivary gland CD4+IL-10+ T 602	
cells. This contrasts in vitro findings demonstrating that ICOS acts downstream of IL-603	
27 in promoting IL-10 production by Tr1 cells in vitro [64]. However, salivary gland IL-604	
10+CD4+ T cells in our model were phenotypically distinct from Tr1 cells. Moreover, 605	
here we examined the influence of ICOS co-stimulation of T cells during virus 606	
persistence rather than during initial T cell activation as studied by Pot et al. 607	
Therefore, although the impact of ICOS on CD4+IL-10+ T cell generation during acute 608	
infection was not examined in our study, these data collectively imply that the type of 609	
IL-10-producing T cell and the timing of IL-10-inducing signals may influence the 610	
relationship between IL-27 and ICOS in the induction of CD4+IL-10+ T cells. Notably, 611	
blockade of ICOS was not accompanied by an elevated virus-specific TH1 responses 612	
d14 pi despite dramatically reducing salivary gland CD4+IL-10+ accumulation. This 613	
	 23	
may reflect a possible dual function for ICOS in positive co-stimulation [65] in addition 614	
to IL-10 induction. However, our data does not preclude a possible role for ICOS and, 615	
possibly, other IL-10-inducing receptors in the suppression of antiviral control during 616	
the latter stages of MCMV persistence.  617	
 618	
We demonstrate that IL-27 is critical for the induction of peripheral IL-10+CD4+ T cell 619	
responses and subsequent suppression of TH1 responses during the persistent 620	
phase of infection. Experiments using anti-IL-27 and anti-IL-10R suggest that early 621	
IL-27-mediated induction of IL-10+ T cells has a long-term impact on antiviral 622	
immunity and virus persistence. However, our data does not preclude an IL-10-623	
independent inhibitory function for IL-27 during the later stages of infection. Indeed, 624	
antagonizing both IL-10R and IL-27 14 days pi led to an additive, albeit modest, 625	
increase in virus-specific IFNγ+CD4+ T cells by day 30 (S7 Figure). Intriguingly, IL-27 626	
can induce dendritic cell expression of the ATPase CD39 [66]. However, in contrast 627	
to IL-27rα-/- mice, mice deficient in the ecto-5’-nucleotidase CD73 that acts 628	
downstream of CD39 in the purinergic system have no alteration in MCMV-specific 629	
memory T cell accumulation and only a moderate and transient reduction in MCMV 630	
replication in the salivary glands [67]. Taken together with data derived from 631	
CD4creIL-10flox and IL-27rα-/- mice, these results collectively suggest that early 632	
induction of IL-10+CD4+ T cells is the dominant mechanism through which IL-27 633	
impinges on anti-MCMV T cell immunity.  634	
 635	
In vivo and in vitro experiments revealed that the induction of IL-27 during MCMV 636	
infection was promoted by type-I IFN. Although the uncontrolled virus replication and 637	
associated disease and inflammation observed in mice treated with anti-IFNαR-1 638	
antibody precluded the assessment of the direct impact of IFNαR-1 signaling on both 639	
IL-27-driven IL-10+ T cell development and virus persistence, our data implies that 640	
type-I IFN may impinge on antiviral immunity via the induction of IL-27. Comparable 641	
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IFN-dependent induction of IL-27 was observed upon in vitro stimulation with either 642	
MCMV or the TLR3 ligand, poly(I:C). Endosomal TLRs including TLR3 are activated 643	
upon acute MCMV infection and induce type-I IFN expression [68,69]. Thus, our data 644	
suggest that MCMV may exploit an immune-regulatory aspect of this “antiviral” 645	
response to promote persistence within mucosal tissue and subsequently increase 646	
the window of opportunity for horizontal transmission via mucosal secretions.  647	
 648	
 649	
 650	
 651	
 652	
 653	
 654	
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Materials and Methods  670	
 671	
Mice, infections and treatments 672	
CD4-Cre-IL-10flox/flox (Cre-)/CD4-Cre+IL-10flox/flox (Cre+) were generated by Werner 673	
Muller (University of Manchester) and were kindly provided by Jean Langhorne 674	
(Francis Crick Institute), 10-BiT mice were given to us by Padraic Fallon (Trinity 675	
College Dublin) and Il-27rα-/- (wsx1-/-), Rag1-/- and Il-10-/- mice were obtained from 676	
The Jackson Laboratory. All mice were bred in-house. C57BL/6 WT mice were 677	
purchased from Charles River or Envigo. Mice were infected with MCMV that was 678	
prepared by sorbital gradient purification as described previously [70]. Mice were 679	
infected with 3 × 104 pfu MCMV intraperitoneally (i.p.). In some experiments, CD4-680	
Cre-IL-10flox/flox mice were administered 2 mg αIFNαR-1 (clone MAR1-5A3, BioXcell) 681	
or IgG1 Isotype control (clone MOPC-21 BioXcell) at the time of infection, or 200 µg 682	
anti-ICOS (clone 7E.17G9 or JmAb51-TM) or IgG control (clone LTF2 or R347-TM), 683	
respectively) on days 6 and 10 pi. In other experiments mice were treated with 500 684	
µg anti-IL-27 (clone MM27-7B1, Biolegend), 250 µg anti-IL-10R (clone 1B1.3A 685	
BioXcell) and also in combination or Isotype control (clone MOPC-21 BioXcell) on 686	
days stated in the legend. In some experiments, CD4+ T cells were isolated from 687	
spleens of C57BL/6 and IL-10-/- mice by negative separation (Miltenyi). 5 x 106 cells 688	
were then transferred intravenously (i.v.) into rag1-/- mice one week prior to MCMV 689	
infection.  690	
 691	
T-cell effector function assays 692	
Leukocytes were extracted from murine spleen, salivary glands and lungs as 693	
described previously [13,60]. For CD4+ functional responses, isolated leukocytes 694	
were stimulated for 2 hours with 3 µg/ml m09, (GYLYIYPSAGNSFDL), M25 695	
(NHLYETPISATAMVI), m139 (TRPYRYPRVCDASLS), and m142 696	
(RSRYLTAAAVTAVLQ) MCMV MHCII peptides (Genscript). Brefeldin A (Sigma) was 697	
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then added and cells incubated for a further 4 hours. For CD8+ functional responses, 698	
leukocytes were stimulated with 2 µg/ml m139, IE3, M38, and M45 MCMV MHCI 699	
peptides in the presence of anti-mouse CD107a-FITC (Biolegend) with monensin 700	
(BD Biosciences) and brefeldin A for 6 hours. Cells were subsequently stained with 701	
Zombie Aqua fixable viability dye (Biolegend) or LIVE/DEAD-Aqua (Life-702	
Technologies), stained with anti-CD16/CD32 Fc-block (Biolegend) and then with 703	
either anti-CD4 Pacific-Blue or PercP, (clone RM4-5, Biolegend) or with anti-CD8 704	
PercP (clone 53-6.7, Biolegend) and anti-CD262 (TRAILR DR5, clone MD5.1, 705	
eBioscience). Cells were fixed, saponin permeabilised and stained for anti-IFNγ FITC 706	
or Pacific-Blue (clone XMG1.2, Biolegend) and anti-IL-10 APC (clone JES5-16E3, 707	
eBioscience). Data was acquired using a BD FACSCantoII flow cytometer (BD 708	
Biosciences) and analysed with FlowJo software (TreeStar).  709	
 710	
Cell phenotyping and IL-27 detection 711	
Direct ex vivo intracellular IL-27 production was detected as previously described 712	
[71]. Cells were stained with a combination of anti-I-A/I-E (clone M5/114.15.2, 713	
Biolegend), anti-CD11c Pe-Cy7 (clone HL3 BD, Pharmingen), anti-Ly6C FITC (clone 714	
AL-21 BD Pharmingen), anti-CD11b APC-Cy7 (clone M1/70, Biolegend), anti-F480 715	
Brilliant-Violet 711 (BV711) (clone BM8, Biolegend), anti-CD45R/B220 BV785 (clone 716	
RA3-6B2, Biolegend), SiglecH APC (clone 551, Biolegend), anti-Ly6G PerCP-Cy5.5 717	
(clone 1A8, Biolegend), and anti-CD3ε BV605 (clone 145-2C11, Biolegend). Cells 718	
were fixed, saponin permeabilised and stained with anti-IL-27 p28 PE (clone MM27-719	
7B1, Biolegend). To determine T cell transcription factor profiles cell were surface-720	
stained with anti-CD4 BV785 (clone RM4-5, Biolegend), anti-CD90/CD90.1 (Thy1.1) 721	
BV650 (clone OX-7, Biolegend) anti-CD130 PE (gp130) (clone KGP13, eBioscience), 722	
fixed and permeabilised using BD Cytofix/Cytoperm solution (BD Biosciences) and 723	
stained with anti-T-Bet BV421 (clone 4B10, Biolegend), anti-BLIMP-1 Alexa-Fluor 724	
647 (AF647) (clone 5E7, Biolegend), and anti-cMaf eFluor 660 (clone sym0F1, 725	
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eBioscience). All data was acquired using a BD LSRForetssa flow cytometer (BD 726	
Biosciences) and analyzed with FlowJo software (TreeStar). For analysis of co-727	
stimulatory ligand expression, cells were surface stained with a combination of anti-728	
CD11c APC-Cy7 (clone N418, Biolegend), anti-I-A/I-E PerCP-Cy5.5 (clone 729	
M5/114.15.2, Biolegend) anti-F480 Brilliant-Violet 421 (BV421) (clone BM8, 730	
Biolegend), anti-CD80 APC (clone 16-0A1, Biolegend), anti-CD86 Pe-Cy7 (clone GL-731	
1, Biolegend), anti-OX40L APC (clone RM134L, Biolegend), anti-4-1BBL PE (clone 732	
TKS-1, Biolegend), anti-CD40 FITC (clone 3/23, Biolegend) and anti-Ly6G PE (clone 733	
1A8, Biolegend), anti-ICOS APC-Cy7 (clone C398.4A, Biolegend), anti-AhR Alexa-734	
Flour 488 (AF488) (clone 4MEJJ eBioscience), anti-CD49b Pe-Cy7 (clone DX5,  735	
Biolegend), anti-LAG3 PE (clone C9B7W, Biolegend) anti-NK-1.1 Pe-Cy7 (clone 736	
PK136, Biolegend), anti-CD19 FITC (clone 6D5, Biolegend), anti-CXCR3 PerCP-737	
Cy5.5 (clone CXCR3-173 Biolegend), and anti-CCR5 AF488 (clone HM-CCR5, 738	
Biolegend). Data was acquired using a BD FACSCantoII flow cytometer (BD 739	
Biosciences) and analysed with FlowJo software (TreeStar). 740	
 741	
Tetramer staining 742	
The following MCMV MHCI biotinylated were refolded and kindly provided by the NIH 743	
tetramer Core Facility- H-2D(b) M45 985-993 HGIRNASFI, H-2k(b) m139 744	
TVYGFCLL,  H-2k(b) M38 316-323 SSPPMFRV, H-2k(b) IE3 RALEYKNL. 745	
Biotinylated monomers were tetramerised as described previously [72]. Isolated 746	
leukocytes were stained with viability dye and then with 25 µg/ml tetramer conjugated 747	
to PE or APC for 15 minutes at 37°C. Cells were subsequently stained with Fc-block 748	
and anti-CD8 APC-Cy7 (clone 53-6.7, Biolegend). Data was acquired using a BD 749	
FACSCantoII flow cytometer (BD Biosciences) and analysed with FlowJo software 750	
(TreeStar). 751	
 752	
Isolation of human T cells from human colon 753	
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Peripheral blood and healthy colon specimens were obtained from patients 754	
undergoing primary tumor resection for colorectal adenocarcinoma at the University 755	
Hospital of Wales, Cardiff. Blood samples were collected on the day of but prior to 756	
surgery. The tissue used in this study was autologous colon samples that were cut 757	
from a macroscopically normal section of the excised tissue, at least 10 cm from the 758	
tumor. Colon tissue was washed in extraction medium consisting of DMEM 759	
supplemented with 100 U/ml Penicillin, 100 mg Streptomycin and 2 mM L-Glutamine, 760	
20 µg/ml Gentamincin and 2 µg/ml Fungizone (all Life-Technologies) as described 761	
previously [73]. Samples were finely cut with scalpel blades in a petri dish and forced 762	
through a 70 µM and subsequently a 40 µM cell strainer. Cells were washed and 763	
pelleted by multiple centrifugations and lymphocytes were isolated using 764	
Lymphoprep (Axis-Shield, Scotland).  765	
 766	
Fluorospot analysis of IFNγ and IL-10 767	
Peripheral blood mononuclear cells (PBMCs) from healthy HCMV sero-positive 768	
healthy volunteers were isolated using Lymphoprep. For target cells, some PBMCs 769	
were γ-irradiated with 3000 Rad, plated out @ 1 × 105 cells/well and pulsed with 2 770	
µg/ml of Peptivator CMV pp65 overlapping peptide pool (Miltenyi Biotec), 2 µg/ml 771	
PepMix HCMVA UL55 overlapping peptide pool (JPT), or with DMSO vehicle control 772	
for 2 hours @ 37°C. CD4+ T cells were then isolated from the remaining PBMCs by 773	
negative selection (Miltenyi Biotec). Pulsed autologous targets were then transferred 774	
to a human IFN+/IL-10+ Flurospot plate thus removing (IL-10-producing) monocytes 775	
that adhered to the plate. 3 × 105 purified CD4+ T-cells and 1/100 human anti-776	
CD28/CD49d co-stimulation antibodies (BD Pharmingen) were then added for 18 777	
hours @ 37°C. E:T ratios ranging from 1:3 to 3:1 were tested. After incubation, plates 778	
were assayed according to the manufacturers instructions (Mabtech) and quantified 779	
using a CTL Immunospot Fluorospot Line plate reader (CTL). Cells were maintained 780	
in RPMI, 100 U/ml Penicillin, 100 mg Streptomycin, 2 mM L-Glutamine (all Life-781	
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Technologies) and 5% human AB serum (Welsh Blood Transfusion Service). 782	
Autofluoresence is adjusted using the analysis software and removed from the final 783	
SFC count. 784	
 785	
For analysis of colon leukocyte cytokine production, PBMCs from the colon donor 786	
was used as autologous γ-irradiated in an identical manner as that described 787	
previously. 1.5 × 105 cells per well and pulsed with peptide pools or DMSO vehicle 788	
control for 2 hours @ 37°C. Cells were transferred to a human IFN+/IL-10+ Fluorospot 789	
plate with the addition of 5 × 104 cells from peripheral blood and Colon processed 790	
tissue with the inclusion of 1/100 human anti-CD28/CD49d co-stimulation antibodies 791	
for 18 hours @ 37°C. Plates were assayed and measured as described above. 792	
 793	
Antibody and cytokine measurements 794	
Cardiac punctures were performed on CD4-Cre-IL-10flox/flox, CD4-Cre+IL-10flox/flox mice 795	
on either naïve mice or after 60 days of MCMV infection and plasma isolated. Plasma 796	
was then assayed for anti-Sjögrens Syndrome Antigen IgG by ELISA (Alpha 797	
Diagnostics). Samples were analysed according to the manufacturers instructions 798	
and Total IgG antibody levels present in the plasma was calculated by interpolation 799	
from the calibrator curve provided with the kit. Excised tissue from both Spleen and 800	
Salivary Gland (approx. 50-100 mg) were weighed, washed and re-suspended in 801	
DMEM. Supernatant was assayed in triplicate for IL-27 p28 production by ELISA and 802	
performed according to the manufacturers instructions (eBioscience). 803	
 804	
Viral load quantification 805	
Infectious virus quantification was determined using plaque assays as previously 806	
described [60]. Viral DNA copy number in saliva was determined using qPCR for 807	
relative expression of IE1, as described previously [74]. Oral lavage was performed 808	
on the sublingual cavity of anaesthetised mice using 20 µl of sterile PBS. 1 µl of 809	
	 30	
sample was used for qPCR and measured using SYBR green (Bio-Rad) using 810	
MCMV IE1 forward (5ʹ-AGCCACCAACATTGACCACGCAC-3ʹ) and MCMV IE1 811	
reverse (5ʹ-GCCCCAACCAGGACACACAACTC3ʹ) primers. PCR was performed 812	
using an MJ Mini Personal Thermal Cycler (Bio-Rad) using the conditions as 813	
described previously [74]. To establish a standard curve, DNA copy/µl was 814	
determined from the known concentration and molecular weight of the MCMV 815	
pARK25 BAC (a kind gift from Alec Redwood, Murdoch University) and assayed for 816	
relative IE1 expression as above.  817	
 818	
Macrophage transcriptomics 819	
WT, IfnαR-/- and Ifnβ1-/- BM-DM were generated as previously described [60]. Cells 820	
were infected with WT-MCMV, MCMVΔIE3 (MOI = 1) or were mock infected [75], and 821	
RNA isolated using RNeasy Mini kit at different time-points (Qiagen) according to 822	
manufacturer’s instructions. Some cells were stimulated with Poly(I:C) (Invivogen). 823	
Quality control (QC) was performed using an Agilent Bioanalyser and, total RNA 824	
labeled. RNA was hybridised to Mouse Gene 1.0ST microarrays (Affymetrix) using a 825	
WT Expression kit (Ambion, UK). GC metrics of captured data were assessed using 826	
Affymetrix Expression Console software and arrays were imported into Partek 827	
Genomics Suite (Partek) for downstream analysis. Arrays were normalised using the 828	
gcRMA algorithm [76] and data was filtered to include genes with at least 1 signal 829	
value of > = 150 across the time course. 830	
 831	
Ethics statement 832	
All mice experiments were performed under the UK Home Office project Licence 833	
(PPL 30/2969). For human colon and PBMC samples, informed consent was 834	
obtained from participants in writing. The Wales Research Ethics Committee granted 835	
	 31	
ethical approval for sample use in this study. For use of HCMV sero-positive donor 836	
PBMC samples used in this study informed consent was obtained in writing. 837	
 838	
Statistics 839	
Power calculations were performed in R using data from a pilot study using CD4-840	
Cre/IL-10 mice. It was determined that a minimum of 5 participants per group would 841	
be needed to detect a difference in means with 90% power and an alpha value set at 842	
0.05. Statistical analysis was performed using the Mann-Whitney U test for paired 843	
analysis of viral-load analysis and flow cytometry data. Where more than 2 groups 844	
were assessed concurrently (viral-load analysis, ELISA analysis), 1-way ANOVA 845	
analysis of data was performed. To assess biological replication: all in vivo 846	
experiments were performed multiple times at different times, as stated in figure 847	
legends. All outliers were included in datasets, as shown. For all tests performed, p 848	
values are reported as *≤0.05, **≤0.01, and ***≤0.001. 849	
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Supporting Information 1110	
 1111	
S1 Figure. CD4+ IL-10+ T cells are not TH17 or Tr1 cells. 1112	
10-BiT reporter mice were infected with MCMV and at day 7 and d14 pi spleen and 1113	
salivary glands were isolated. Representative histograms of AhR viable (aqua live/dead-) 1114	
Thy1.1
-
 or Thy1.1
+
 expression by CD4+CD3+ cells (top), control = fluorescent minus one-1115	
stained Thy1.1
+
 samples. Representative bivariant FACS plot of CD49b/LAG3 viable 1116	
(aqua live/dead-) expression by CD4+CD3+ cells (bottom). 1117	
 1118	
S2 Figure. Non-T cells do not produce compensatory IL-10 in CD4-Cre+IL-10flox 1119	
mice. 1120	
CD4-Cre-IL-10flox/flox(Cre-) and CD4-Cre+IL-10flox/flox (Cre+) mice were infected with MCMV 1121	
and at day 7 and 14, IL-10 responses in the spleen and salivary glands were measured. 1122	
Representative bivariant FACS plots of CD19
+
 and NK1.1
+
 versus IL-10 expression 1123	
splenic (top) and salivary gland (d14 bottom) were analysed by viable (aqua live/dead-), 1124	
CD19
+
/CD3
-
 and NK1.1
+
/CD3
-
 expression. Data is representative of 6 mice per group. 1125	
 1126	
S3 Figure. Increased co-stimulatory ligand expression in the absence of T cell-1127	
derived IL-10 during MCMV infection 1128	
CD4-Cre-IL-10flox/flox(Cre-) and CD4-Cre+IL-10flox/flox (Cre+) mice were infected with MCMV 1129	
and at day 7 and 14, myeloid expression in the spleen (A) and salivary glands (B) was 1130	
measured. CD11c
+
MHCII
+
 were quantified (left) and % CD80, CD86, OX-40L, 4-1BBL 1131	
and CD40 expression (right) was assessed. Data is representative of 5-6 mice per 1132	
group. 1133	
 1134	
S4 Figure. MCMV does not induce autoimmunity in the absence of IL-10 1135	
production by CD4+ T-cells  1136	
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(A) CD4-Cre-IL-10flox/flox (Cre-) and CD4-Cre+IL-10flox/flox (Cre+) mice were infected with 1137	
MCMV and at day 14 and 30 Spleen and Salivary Glands were isolated and 1138	
CD4+/DR5+ cells were quantified. Mean ± SEM of total cells from 4-12 mice are 1139	
shown and represent 2 separate experiments. (B) Cardiac punctures were performed 1140	
d60 pi and anti-SSA IgG was measured by ELISA. Data is representative of 6 naïve 1141	
and 16 mice in each group and is representative of 2 experiments.  1142	
 1143	
S5 Figure. MCMV-specific memory CD8+ T-cell inflation is increased in the 1144	
absence of IL-27R signaling 1145	
Il-27rα-/- or WT mice were infected with MCMV and total virus-specific CD8+/IFNγ+ and 1146	
CD8
+
/CD107a
+
 T-cells were quantified. Data is presented as mean ± SEM of 5 mice and 1147	
is representative of 2 experiments. 1148	
 1149	
S6 Figure. ? ICOS treatment does not impact on CD4 TH1 responses. 1150	
WT (C57BL/6) mice were infected with MCMV and at d6 and d10 pi. 200 ?g Isotype 1151	
control or 200 ?g ? ICOS was administered. At d14 pi splenic virus-specific 1152	
CD4+/IFN? + responses were quantified and expressed at mean + SEM of 6 1153	
mice/group. 1154	
 1155	
S7 Figure. Antagonizing of IL-10R and IL-27 during chronicity results in modest 1156	
increase in virus-specific IFNγ+CD4+ T cells  1157	
WT (C57BL/6) mice were infected with MCMV treated with anti-IL-10R, anti-IL-27, 1158	
and/or isotype on day 14 pi, and at d30 pi spleen CD4+/IFNγ+ responses were 1159	
quantified and expressed as mean ± SEM of 4 mice/group. 1160	
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